Cryo-Cell International, Inc. (CCEL) - Form 8-K Summary
Business Context and Reporting Period
Cryo-Cell International, Inc. filed this Current Report on Form 8-K on March 12, 2026, regarding an event that occurred on March 9, 2026. The company is incorporated in Delaware and its common stock trades on NYSE American under the symbol "CCEL".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status.
Material Changes
On March 9, 2026, the Company received a written notice from NYSE American LLC stating it is not in compliance with the continued listing standards set forth in Section 1003(a) of the NYSE American Company Guide. The specific standard violated is not detailed in this text. Trading of the common stock continues without immediate interruption while the Company pursues a plan to regain compliance.
Outlook, Risks, and Management Commentary
- Compliance Plan: The Company intends to submit a plan of compliance to NYSE American by April 8, 2026.
- Extension Possibility: If the plan is accepted, NYSE American may grant an extension of time to regain compliance.
- Risks: There is no assurance that NYSE American will accept the Company's plan or that the Company will be able to regain compliance within any granted extension period. Failure to regain compliance could result in delisting.
Investor Verification Checklist
- Verify the specific listing standard (Section 1003(a)) the company failed to meet, likely related to share price or market value.
- Monitor the submission of the compliance plan by the April 8, 2026 deadline.
- Review the press release (Exhibit 99.1) for additional details on the notice and management's immediate response.
- Assess the risk of potential delisting if the compliance plan is rejected or the extension period expires without resolution.